Incyte (INCY) and Moderna (MRNA) on Torvanta's measures: INCY grades higher on 3 of the 4 factor families and MRNA on 1.
| INCY | MRNA | |
|---|---|---|
| Value grade | A- | n/a |
| Growth grade | A+ | n/a |
| Profitability grade | A | F |
| Momentum grade | C | A+ |
| Market value | $22.8B | $81.1B |
| P/E (trailing) | 16.1x | n/a |
| Forward P/E (Torvanta estimate) | 10.7x | n/a |
| Revenue, last 12 months | $5.4B | $2.2B |
| Revenue growth (y/y) | +21% | -28% |
| Operating margin | 30.0% | -149.0% |
| Return on invested capital | 60.1% | -46.6% |
| Free-cash-flow yield | 6.7% | -1.5% |
| Total return, 1 year | +31.4% | +613.3% |
| Total return, 3 years | +94.1% | +97.4% |
Full INCY analysis · Full MRNA analysis
Incyte (INCY) and Moderna (MRNA) on Torvanta's measures: INCY grades higher on 3 of the 4 factor families and MRNA on 1. Which fits an investor depends on their goals; this is research, not a recommendation. Subscribers see where the model ranks each and its expected return.
On trailing earnings INCY trades at 16.1x and MRNA at n/a; their value grades are A- and n/a against their sectors.
Subscribers get the model's rank and expected return for every covered company, the reasoning behind each, and the Torvanta model portfolio's trades each trading day, sized and explained, at three risk levels.
See plans Or get the free weekly newsletterTorvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.
All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer